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Research Article
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The gastrointestinal tract is a complex niche and the main port of entry of many pathogens that trigger
a wide range of diseases like inflammatory bowel disease (IBD) and colon cancer. Antibodies are
effective for treating such diseases, but a system capable of local delivery at the site of the pathology,
thus avoiding systemic side effects, is not yet available. Here we report a novel recombinant
scFvSIgA1 protein produced by Lactococcus lactis, anchored to the bacterial membrane, which
retains its full immuno-recognizing potential. This scFv fragment employed was specific for a colon
cancer epitope, epithelial glycoprotein protein-2 (EGP-2). Accordingly L. lactis expressing this chi-
meric protein was capable of binding cells expressing this epitope. Expression of specific antibodies
on bacteria may allow local delivery of anticancer agents produced by such bacteria in conjunction
with the antibody and provides a new avenue in the quest for targeted drug delivery.
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1 Introduction
The gastrointestinal tract is the locus for many different
pathologies, including cancer and inflammatory disease,
whose treatment remains problematic. Although substantial
insight has been gained in the pathogenesis of these dis-
eases [1, 2], translating this knowledge to novel therapy
remains troublesome. These problems derive from the diffi-
culty of delivering functional protein therapeutics to the
mucosa of the digestive tract, mainly as a consequence of
the protein-structure hostile nature of the lumen of the tract
and the occurrence of unwanted side effects when such pro-
teins are introduced in a systemic fashion. Molecules that
normally reside in the tract, however, should be able to
withstand protein degradation. The principal antibody on
most mucosal surfaces is secretory Ig A (SIgA). It is a poly-
peptide complex consisting of dimeric IgA, the linking J
chain and the secretory component (SC). Its molecular
stability and its in general anti-inflammatory properties
make SIgA an apparently ideal molecule to function in pas-
sive protective immunity strategies involving its exogenous
application to mucosal surfaces. Obvious candidates for
such a strategy are conditions in the levels of endogenously
Correspondence: Dr. Nicolaas A. Bos, Department of Cell biology,
Section Immunology, University Medical Center Groningen (UMCG),
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produced IgA are reduced, e.g., in selective IgA deficiency,
and in HIV patients IgA is reduced or absent. Similar condi-
tions appear when patients are treated with immunosup-
pressive drugs. Evidently, however, immunoneutralization
of specific disease-related proteins is also an exiting possi-
bility (e.g., neutralization of mucosal TNF in Crohn's dis-
ease; [3]). The possible use of SIgA for the treatment of dis-
ease is further facilitated by the advent of DNA recombi-
nant technology which now enables the generation of so
called chimeric minibodies incorporating selective anti-
body fragments (single chain variable fragments, scFv).
The problem however as to how to get such molecules at
their intended site of action in the digestive tract remains.
Poly Ig receptor (pIgR) is expressed on all the intestinal
epithelial cells [4]. Dimeric IgA, secreted by the plasma
cells, binds to the pIgR present on epithelial cells of the
mucosa and is subsequently transported to the lumen of the
gut. Then the IgA is released into the gut lumen together
with the extracellular part of the pIgR as SIgA [5]. pIgR is
composed of six domains, with the sixth domain containing
the protease cleavage site. This cleavage site on the pIgR
can be exploited for specific drug delivery because epithe-
lial cells have protease activity capable of specifically
hydrolyzing and cleaving this site in the complex. A part of
the pIgR remains bound to the polymeric Ig to become
SIgA or SIgM.
A specific receptor for the IgA Fc region (FcaRI) exists;
it is a novel apoptotic unit active systemically but not in the
mucosa. In addition to its anti-inflammatory and inhibitory
signaling action, it seems essential for controlling tumor
growth [6]. A number of reports showed that therapeutic
antibodies are able to trigger immune responses via FcaRI.
These antibodies can either be intact IgA or bispecific anti-
bodies (BsAb) that recognize both the ectodomain for
FcaRI and the tumor antigen of interest [7]. In a compari-
son of hapten-directed antibodies of different human iso-
types, IgA2 was found to be more effective. Also, IgG iso-
types recruits neutrophils and induces tumor cell death [7].
Similarly, an IgA1 antibody against EpCAM proved more
effective than IgG1 recruiting neutrophils to kill EpCAM-
positive tumor cells in solid tumors [8]. Ideally, such anti-
bodies would only be delivered at the intended site of
action, i. e., the digestive tract where the EpCAM-bearing
colon (pre-) cancer cell resides, but strategies for gut-spe-
cific delivery have been poorly researched hitherto.
Despite the high production costs and the occurrence of
systemic side effects, antibody-based immunotherapy has
become an effective treatment for a number of different
cancers. Therapeutic mAb can be used to induce tumor cell
death by a variety of mechanisms. For example, by cross-
linking antigens on tumor cells leading to apoptosis, cell
cycle arrest or the inhibition of cell proliferation [9].
Smaller recombinant engineered antibody fragments and
variants thereof are now emerging as credible conventional
antibody-based immunotherapy. These fragments preserve
the targeting specificity of whole mAbs and can be eco-
nomical, furthermore possess a wide range of diagnostic
and therapeutic efficacy. The first clinical trial using scFv
in ovarian cancer patients was reported in 2000 by the group
of Alvarez et al. [10]. This successful clinical trial opened a
new era to many recombinant antibodies fragment variants
like diabodies, triabodies, etc. These fragments are exten-
sively studied in various human carcinomas such as color-
ectal, breast, and small cell lung cancer [11–13]. The possi-
bility to engineer this treasure of immunoneutralizing DNA
sequences into stable IgA molecules greatly adds to the
appeal of SIgA exotherapy, despite the as yet unsolved pro-
duction and delivery problems.
A possible target for SIgA exotherapy is epithelial glyco-
protein-2 (EGP-2), a well-established target antigen in col-
orectal cancer that is overexpressed on the cell surface of
various human cancinomas [11, 12]. Whereas in normal
epithelia, EGP-2 expression is limited to the baso-lateral
membrane and thus inaccessible for SIgA molecules
present in lumen of the tracts, colorectal cancer cells lose
this polarity of EGP-2 expression [14, 15]. The advantage
of targeting EGP-2 is that it is not present in the circulation
and has been extensively studied in antibody-mediated
imaging [16–18]. The minibody MOC31 scFv-Fc recog-
nizes human EGP-2 and harbors human constant gamma 1
chain Fc domain and is thus ideally suited for engineering
into SIgA for colon cancer SIgA exotherapy. Such SIgA
exotherapy still critically awaits a solution to the delivery
problems.
Importantly a new mucosal delivery strategy has
emerged via the execution of a first clinical trail using
transgenic Lactococcus lactis producing IL-10 to treat
Crohn's disease, which was published by Braat et al. [19]. If
L. lactis can be coached to produce scFv, the window to
clinically useful SIgA exotherapy for colon cancer therapy
and for other treatment diseases, will be opened. This con-
sideration prompted us to construct scFvMOC31 IgA for
targeting colon cells employing L. lactis as a heterologous
expression system. The fragment antigen binding (Fab)
region was derived from mAb MOC31 that can recognize
EGP-2 and it was extended with constant a gene. The sixth
domain (Sc) contains the cleaving sites and the remaining
five domains of pIgR were cloned resulting in MOC31-
SIgA1. Finally, we expressed this scFv as a part of natural
membrane protein of L. lactis bacteria. Membrane expres-
sion was confirmed by Western blotting. Despite these
many changes in the MOC31 protein, it could still recog-
nize the EGP-2 antigen which was transiently expressed on
the Ramos B cells. Thus, in this paper, we report an impor-
tant next step in the quest for anticolon cancer SIgA exo-
therapy. Furthermore, the ability of antibody-expressing
bacteria to bind to specific motifs also enables specific tar-
geting to cell expressing such motifs and should thus allow
treatment of these cells with bacterially produced products
co-engineered into the bacteria with the antibody.
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2 Materials andmethods
2.1 Construction of scFvMOC31IgA1/2
The Ca1/2 genes were amplified from normal ileum of
human cDNA with EcoRI/HindIII restriction sequences
(Table 1) using PCR method. Cc1 region present in
MOC31IgG plasmid [13] was replaced with Ca1 and Ca2
using above mentioned restriction enzymes to get MOC31-
IgA1 andMOC31-IgA2 constructs, respectively (Fig. 1B).
2.2 Construction of scFvMOC31IgA1SC1
The sixth domain of human SC was amplified from SC-
his6 plasmid [20] and was designated as SC1. MOC31S-
C1IgA1 and MOC31SC1IgA2 were constructed by insert-
ing SC1 using BglII/PfoI restriction enzymes into MOC31-
IgA1 andMOC31-IgA2 (Fig. 1C).
2.3 SC2
The remaining five domains of human SC (referred as SC2)
were amplified from SC-his6 plasmid. For subcloning,
59HindIII and 39 Van91I were introduced in SC2. The entire
five domains were cloned into the MOC31SC1IgA1 and
MOC31SC1IgA2 to get MOC31SIgA1/SIgA2 (Figs. 1D
and 2A).
2.4 pNZmlePSIgA1
pNZmleP produce a membrane protein that is a malate
transporter protein in L. lactis. The pNZmleP was con-
structed as described in ref. [21]. To ligate the entire
MOC31SIgA1 into the pNZmleP, AflIII restriction site was
used. An additional AflIII restriction site was added at the 39
end of the MOC31SIgA1 by PCR. MOC31SIgA1 was
ligated at the C-terminal of the mlep gene at the AflIII
restriction site (Table 1). Only the cells with the right orien-
tation plasmid can grow. Because the AflIII restriction
enzymes digest ACRYGTand we used different nucleotides
at the beginning and at the end of the MOC31SIgA1
sequence. Ligation mixtures were transformed to L. lactis
NZ9000 using an electroporation protocol described by
Holo and Nes [22] (Fig. 2b).
2.5 COS-7 cells transfection
Two six-well plates of COS-7 cells were transiently trans-
fected with supercoiled plasmid DNA using the GeneJam-
mer transfection reagent (Stratagene) according to the man-
ufacturer's recommendations. Transfection efficiency was
normally in the range of 5–10%. After 2 days, one trans-
fected plate was fixed with acetic acid and ethanol. These
cells were used for immunofluorescent staining. The second
plate was incubated for 3 days and scFvSIgA1 protein con-
ditioned medium was aspirated and stored at –208C until
analysis. The rest of the COS-7 cells were washed twice
with PBS, pelleted, and stored at –208C until analysis.
Later, the proteins from these cells were extracted and
stored at –808C.
2.6 Bacterial strains, growth condition, and
induction of proteins
In our experiments Escherichia coli K-12 strain was grown
on LB agar and broth. The cells were induced by IPTG to
produce the proteins. L. lactis strain NZ9000 was cultivated
semianaerobically at 308C in M17 broth at pH 6.5, supple-
mented with 1.0% (w/v) glucose and 5 lg/mL chloramphe-
nicol when carrying pNZmleP or derivatives. For isolation
of membrane vesicles, cells were grown to an OD600 of 1,
after which transcription from the nisA promoter was
switched on by the addition of 0.2% v/v culture supernatant
of the nisin A producing strain NZ9700 [23]. Cells were
harvested 1 h after the induction of nisin.
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Table 1. Primer list, which was used to amplify different gene to construct scFv SIgA
Serial no. Primer name Primer sequence Restriction enzyme
sites
Gene of interest to amplify
1 IgAEcoRI2F CTAGAATTCCCGACCAGCCCCAAGG EcoRI C a region
2 IgAHIndIII2B CGAAAGCTTGTAGCAGGTGCCGTCCA HindIII C a region
3 SC1bgl2kas1F AGATCTTAGGCGCCGACGCTGCTCCTGATG BglII & Kas1 SC1 sixth domain of PIgR
4 SC1pfo1afl2B TCCTGGACTTAAGCTGCCGGAATCCAC PfoI & AflII SC1 sixth domain of PIgR
5 SC2hind3cla1F CAAGAAGCTTATCGATTTTGGTCCCGAGGAGGTG HindIII & ClaI SC2 five domains of PIgR
6 SC2van91sal1B AATCCATAGGTTGGTTAGTCGACCGCTGCCTTCCTCTC Van91 SalI SC2 five domains of PIgR
7 extraSC1Afl2age1cla1F CTTAAGACCGGTTATCGATGCTGCTC AflII, AgeI, ClaI Extra SC1 sixth domain of PIgR
8 ExtraSC1Pfo1B TCCTGGAGAATCCACAGATG PfoI Extra SC1 sixth domain of PIgR
9 LL-AflIII-startsIgA-F ACGCGTCCACCATGGAGACAGA AflIII Extra Afl III site
10 LL-AflII-BssHI-sIgA-B ACTTAAGGCGCGCCTGCCGGAATCCACA AflII, BssHI Extra Afl III site
11 Van91I-AflIII end-sIgA F CCAACCTATGGACGTGTATGAATGGGAGCAGTG Van91I Extra Afl III site end SIgA
12 MunI-end-sIgA B CAATTGGTTCAGGGGGAGGT MunI Extra Afl III site end SIgA
The restriction enzymes introduced into the vector are underlined and bold.
S. Yuvaraj et al. Mol. Nutr. Food Res. 2008, 52, 913–920
2.7 Membrane vesicle preparation of
MOC31pNZmlepSIgA1
Cell were washed with 100 mM KPO4, pH 7.0 and then
resuspended in 100 mM KPO4, pH 7.0 with 20% glycerol.
Cells were recaptured in a bead beater at force 6.5 for 30 s
for three times. Whole cells were removed by centrifugation
at 160006g for 15 min and membrane fractions were iso-
lated by centrifugations at 2670006g for 30 min. Vesicles
were resuspended in 100 mMKPO4, pH 7.0 with 20% glyc-
erol and stored in –808 until used.
2.8 Immunofluorescent staining
Cover slips containing transfected cells were fixed with
ethanol and acetic acid. The cells transfected with MOC31-
IgA variants were stained with antihuman IgA-FITC
(Dako). MOC31-IgG transfected cells were stained with
Alexa fluor 488 goat antihuman IgG (H + L) (molecular
probes). DAPI was used to counter stain the nuclei.
2.9 Enzyme-linked immunosorbent-assay (ELISA)
scFvMOC variant levels in cultured supernatant and in pro-
tein extract were measured with an IgA- and IgG-specific
ELISA. Duplicate wells of serially diluted supernatants
were analyzed as described previously [24].
2.10 Jurkat and Ramos cells FACS
Human cell lines Jurkat and Ramos were stably transfected
with EGP-2 as described previously [14] and cultured in
RPMI (invitrogen) media supplemented with 15% fetal calf
serum. These cells were incubated for 30 min with trans-
fected COS-7 supernatant and protein extract of different
MOC variants. After a brief wash the cells were incubated
with goat antihuman IgA-PE. The FACS analysis was per-
formed on Coulter EpicTM Elite flow cytometer. Data were
analyzed by using Flowjo software version 5.4.5 according
to the manufactures protocol (Tree Star).
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Figure 1. Schematic representation of scFvSIgA development from MOC31IgG with the plasmid size and proteins prediction with
their important properties.
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2.11 Western blotting
Expression of all MOC31 scFv variants were confirmed by
Western blotting. The expected size of proteins and percent-
age of the gels are described in the Table 2 and gels were
stained with comassie blue. For immunodetection, samples
were separated by reduced SDS-PAGE and electrotrans-
ferred to a nitrocellulose membrane. The membrane was
blocked with 5% nonfat milk in PBS-T buffer (PBS con-
taining 0.05% Tween 20), and then incubated with different
(Table 2) antibodies separately for 2 h. The membrane was
washed three times with PBS-T buffer and then incubated
in HRP conjugated secondary antibody for 1 h. The mem-
brane was washed three times with PBS-T buffer and the
expressed proteins were visualized using ECL plus Western
blotting detection system (Amersham).
3 Results
3.1 Construction of scFvMOC31: SIgA1
DNA encoding the Ca1 and Ca2 of IgA1/IgA2 was gener-
ated by PCR. The resulting 1081 and 1053 bp PCR product
encoded amino acids 330 and 317 of Ca1 and Ca2, respec-
tively. These DNA fragments were inserted separately in
the EcoRI and HindIII of eukaryotic expression vector
pMOC31IgG1, yielding plasmid pMOC31IgA1/IgA2.
Sequence analysis confirmed the correct and in-frame of
the pMOC31IgA1/IgA2 (data not shown).
3.2 SC1
SC1 is the sixth domain of the SC that contains the proteo-
lytic cleavage site. SC1 DNA fragment was amplified from
the entire SC vector. BglII and PfoI that are present within
the framework one region were used for inserting the SC1.
Using these restriction sites, 58 nucleotides from the end of
FR1 and beginning of CDR1 region were deleted. This
resulted in a new plasmid pMOC31IgA1SC1.
3.3 SC2
SC2 contained the two domains of the SC was amplified
with HindIII and Van91I site. A stop was inserted at the
beginning of the second domain, because the domains 3 and
4 are used by the Streptococcus pneumoniae to invade the
epithelial cells [25]. The resulting 700 bp PCR product was
successfully cloned into the MOC31IgA1SC1 plasmid to
get MOC31SIgA1.
3.4 pNZmlePSIgA1
The entire MOC31SIgA1 was ligated to the plasmid
pNZmleP at the AflIII restriction site. AflIII has a special
feature since it recognize ACRYGT (where R stands for A
or G and Y for C or T). In plasmid pMOC31SIgA this rec-
917
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Figure 2. (A) Schematic representation of scFvSIgA
expressed on L. lactis membrane protein mlep, (B) Detail
description of the entire scFv MOC31SIgA with their respec-
tive functions.
Table 2. The scFvSIgA was developed from the backbone MOC31IgG







Primary antibody used Secondary antibody used
1 pMOC31IgG 498 54.47 10 1. Antihuman IgG-HRP, 1. –
2. Mouse anti-HA 2. Antimouse-IgG-HRP
2 pMOC31IgA1 603 64.54 10 1. Antihuman IgA-HRP, 1. –
2. Mouse Anti-HA 2. Antimouse-IgG-HRP
3 pMOC31IgASC1 638 68.05 10 1. Antihuman IgA-HRP, 1. –
2. Mouse anti-HA 2. Antimouse-IgG-HRP
4 pMOC31SIgA1 1188 128.53 8 1. Antihuman IgA-HRP, 1. –
2. Mouse Anti-HA 2. Antimouse-IgG-HRP
5 pNZmleP 446 47.79 12.5 1. Rabbit Anti-his 1. Antirabbit-IgG- HRP
6 pNZmlePSIgA(scFv SIgA) 1675 140.84 6 1. Antihuman IgA-HRP, 1. –
2. Rabbit Anti-his 2. Antirabbit-IgG-HRP
This table contains the number of amino acid of each MOC31 vector, their expected size of proteins. To confirm their expression the
proteins was probed with different specific antibodies.
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ognizes site is ACGTGTat the 39 end and ACGCGTat the 59
end. This was very much equivalent of using two different
restriction enzymes.
3.5 COS-7 cells transfection
COS-7 cells were transiently transfected with the entire
MOC31 variant. Right orientation of the constructs was
validated by this method as well as by sequencing. The
transfection efficiency of eukaryotic expression vector
MOC31SIgA1 was 10% as shown by immunopositive for
antihuman IgA-FITC antibodies (Fig. 3). The presence of
secreted scFv MOC31 variants in the transfected COS-7
cells supernatant were analyzed by ELISA (data not
shown). The positive control MOC31IgG1 was produced in
higher quantity than the other scFv variants.
3.6 Western blotting
Western blotting was performed on all the MOC variants.
MOC31 transfected COS-7 supernatant and COS-7 cell
lysate were used for Western blotting. All the products gave
a expected band with a correct size (Fig. 4). Membrane
vesicles were prepared from MOC31pNZmlePSIgA1 fol-
lowed by Western blotting for pNZmleP and pNZmlep-
SIgA1. Total protein precipitation of L. lactis with TCA
was performed and used for Western blotting. From the
above set of experiments we concluded that all the MOC
variants were produced, but with a low yield. In order to test
the functional activity of these proteins, the following
experiments where performed.
3.7 Jurkat and Ramos cells FACS
Flow cytometric analysis of the EGP-2 retrovirally trans-
duced cell lines Jurkat and, Ramos cells confirmed the cell
surface expression of EGP-2. MOC31-IgA containing
supernatant were able to bind to these EGP-2 on these cell
surfaces and gave strong increase in percentage of staining
by functionally active scFv. The binding of MOC31-IgA
containing supernatant to the EGP-2 expressed Ramos cells
proves that IgA is indeed functional (Fig. 5).
4 Discussion
The clinical trail employing IL-10 expressing L. lactis for
the treatment of Crohn's disease has demonstrated that such
bacteria constitute a viable strategy for the mucosal deliv-
ery of therapeutically interesting proteins [19]. This consid-
eration prompted us to explore the potential usefulness for
such bacteria to deliver the gut-stable IgA molecules. This
would be important because already a large variety of anti-
body fragments is available and immunoneutralizing a large
spectrum of clinically interesting molecules and their local
production in a gut-stable fashion could be exceedingly use-
ful. Here we report a novel recombinant scFvSIgA1 protein
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Figure 3. COS-7 cells were transfected with MOC31 vectors,
followed by staining with antihuman IgA FITC and DAPI.
Figure 4. Analysis of recombinant scFv polypeptide, proteins expression and their identity confirmed by immunodetection using spe-
cific antibodies. The polyacrylamide with different percentage of SDS-containing gels was prepared. The Mr of the scFv and Ab indi-
cated was calculated from protein markers run in parallel.
Mol. Nutr. Food Res. 2008, 52, 913–920
produced by L. lactis anchored to their membrane which
retains its full immuno-recognizing potential. As a model
of an example intestinal disease for which such SIgA exo-
therapy might be useful, we targeted our scFv to colon can-
cer. With the recent advances in molecular biology, it has
become possible to translate improved characterization of
tumor antigens to tailored design of recombinant antibodies
specific for these antigens. ScFv molecules on their own
generally do not have any built-in effector capacity nor are
they able to engage natural effector molecules. We gener-
ated an eukaryotic expression plasmid, scFvSIgA1, that
specifically could recognize antigen. To demonstrate the
usefulness of our vector system we analyzed it specificity
by binding to EGP-2 antigen, but it is obvious that the same
strategy can be employed with any scFv fragment.
Upon exposure to nontolerated antigens, the human
humoral immune response generated a remarkable range of
antibodies. In this study we attempt to design tumor target-
ing human recombinant scFvSIgA1 with binding specific-
ity for the antigen EGP-2. This molecule contains an anti-
gen binding site (Fab) which specifically binds to the EGP-
2 antigen, constant a gene as their Fc region and the SC
domains. The sixth domain of SC that contains the cleavage
site was designated as SC1 and was inserted at the begin-
ning of the Fab region and other domains of SC were
included after the Fc region (Fig.2). EGP-2 is abundantly
present in the cells of human carcinomas of different origins
and more importantly such carcinoma cells express this
protein at apical side of the cell (in contrast to untrans-
formed cells) making this epitope accessible for SIgA from
the lumen. Various mAbs directed against EGP-2 have been
extensively studied in diagnostic and therapeutic
approaches in cancer [14, 15]. As colon cancer which also
express high amount of EGP-2, this disease is a candidate
for experimental treatment with the scFvSIgA producing
organism created in the present study. In this context it is
especially interesting that the antibody can be used to target
the bacterium to the cancer cell, whereas a secondary pro-
duced bacterial product can then be employed to kill the
cancer cell. In this context it is important to mention that
whereas the SC2 part makes the scFvSIgA more stable [26]
in the intestinal niche, the SC1 contains a peptidase cleav-
age site. This site can be cleaved by the protease enzymes
produced by the epithelial cells. By fusing small molecules
like cytokines or signaling molecules between the SC1
could be delivered locally to the affected cells.
The IgA Fc region was used to construct scFvSIgA
because IgA is a mucosal Ig and contains intrinsic proper-
ties generally considered to confer protection to the Ig in
the hostile gut environment. Many monoclonal antibodies
and scFv are specifically targeted against EGP-2 in tumor
related to systemic immunity [27]. These antibodies or the
scFv contains the IgG Fc region. Upon binding to the Fc
receptor on effector cells they elicit effector function like
antigen–dependant cell-mediated cytotoxicity (ADCC),
complement dependent cytotoxicity (CDC) response and
apoptosis [28]. It is well documented that FcaRI elicit
immune responses more efficient than IgG Fc receptors
[29]. Overall it seems that the use of IgA Fc region may be
superior both in terms of stability of the chimeric molecule
and in terms of bioeffectivity, and thus offers advantages
for the development of antibodies to treat intestinal carci-
noma and other mucosal disease.
Delivery of therapeutical proteins locally have many
advantages over the administrating systemically [30]. This
recombinant human scFvSIgA is successfully expressed on
the surface of the bacteria like L. lactis which is generally
regard as safe (GRAS). Hence, delivery via oral administra-
tion of the organism for treating gastrointestinal cancer
cells should be possible. Interestingly, the specificity of the
antibody can be altered by changing the Fab region. By
selecting appropriate VH genes one can generate natural
antibodies or pathogen specific antibodies, of obvious
interest for treatment of IgA deficiency patients or other
intestinal diseases.
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Figure 5. Ramos cells were transfected with EGP-2. Supernatants of COS-7 cells which were transfected with different MOC31
vector was incubated with transfected Ramos cells. This was followed by FACS analysis, to show MOC variant retains its binding
properties.
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